Enlil has achieved a significant milestone in Q1 2026 by onboarding eight new MedTech customers, showcasing a shift towards integrated AI-powered traceability solutions in the medical device sector.
During the first quarter of 2026, Enlil welcomed a diverse group of eight MedTech innovators, ranging from organ perfusion to AI-driven imaging, all opting to transition from legacy quality and product lifecycle management (PLM) systems. This trend indicates a broader movement within the MedTech industry towards unified platforms that streamline product development processes, enhancing efficiency and collaboration.
The new customers, including Vascular Perfusion Solutions and iSono Health, highlighted several key factors influencing their decisions. These include the flexibility to customize workflows, a supportive vendor culture attuned to the rapid pace of MedTech innovation, and the integration of quality and lifecycle management into a single platform. Enlil’s architecture allows for a more cohesive data environment, enabling advanced AI capabilities that traditional systems struggle to provide.
As Enlil continues to build on this momentum, the company emphasizes the importance of a unified data foundation for regulatory compliance and operational efficiency. This approach not only accelerates onboarding but also positions Enlil as a critical player in the evolving landscape of MedTech, where agility and innovation are paramount for success.